GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Author:
Affiliation:
1. Diabetes Research Centre, Department of Life and Health Sciences, Ulster University, Coleraine, Northern Ireland
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2192865
Reference129 articles.
1. World Obesity Federation. World obesity atlas. 2022
2. World Health Organization. European regional obesity report 2022. Copenhagen: WHO; 2022
3. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.
4. Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?;Peptides;2024-09
2. Chronic exposure to incretin metabolites GLP-1(9−36) and GIP(3−42) affect islet morphology and beta cell health in high fat fed mice;Peptides;2024-08
3. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23
4. Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity;Expert Opinion on Investigational Drugs;2024-07-17
5. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review;The Journal of Headache and Pain;2024-07-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3